Resumen de acción GOV Insulet Corporation desarrolla, fabrica y vende sistemas de administración de insulina para personas con diabetes insulinodependiente. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Insulet Corporation Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Insulet Precios históricos de las acciones Precio actual de la acción US$268.40 Máximo en las últimas 52 semanas US$273.10 Mínimo de 52 semanas US$147.20 Beta 1.22 Cambio en 1 mes 6.97% Variación en 3 meses 24.72% Cambio de 1 año 49.82% Variación en 3 años 27.08% Variación en 5 años 46.67% Variación desde la OPV 2,244.10%
Noticias y actualizaciones recientes
Insulet Launches Revolutionary Omnipod 5 in Five More Countries in Europe Jan 14
Insulet Corporation to Report Q4, 2024 Results on Feb 20, 2025 Jan 10
Now 25% overvalued after recent price rise Nov 08 Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024
Omnipod 5 App for Iphone Now Fully Available in the United States Oct 30
Insulet Corporation to Report Q3, 2024 Results on Nov 07, 2024 Oct 01 Ver más actualizaciones
Insulet Launches Revolutionary Omnipod 5 in Five More Countries in Europe Jan 14
Insulet Corporation to Report Q4, 2024 Results on Feb 20, 2025 Jan 10
Now 25% overvalued after recent price rise Nov 08 Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024
Omnipod 5 App for Iphone Now Fully Available in the United States Oct 30
Insulet Corporation to Report Q3, 2024 Results on Nov 07, 2024 Oct 01
Independent Chairman recently sold €1.0m worth of stock Sep 13
Insulet Corporation Announces Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes Aug 27
Second quarter 2024 earnings released: EPS: US$2.69 (vs US$0.39 in 2Q 2023) Aug 09
Insulet Corporation to Report Q2, 2024 Results on Aug 08, 2024 Jul 09
Insulet Corporation Announces SECURE-T2d Pivotal Trial Results Demonstrate Omnipod 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes Jun 22
Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands Jun 21
Independent Chairman recently sold €1.2m worth of stock Jun 13
Investor sentiment improves as stock rises 16% May 20
First quarter 2024 earnings released: EPS: US$0.74 (vs US$0.34 in 1Q 2023) May 10 Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024
Insulet Corporation, Annual General Meeting, May 22, 2024 Apr 10
Insulet Corporation to Report Q1, 2024 Results on May 09, 2024 Apr 04 Insulet Corporation Appoints Ana Maria Chadwick as Executive Vice President, and Treasurer, Effective April 22, 2024
Insulet Corporation Presents Positive Results from its First Randomized Controlled Trial (RCT) Showing Improved Glycemic and Patient-Reported Outcomes in Type 1 Diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) Mar 09
Insulet Corporation to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17Th International Conference on Advanced Technologies & Treatments for Diabetes Mar 06
Investor sentiment deteriorates as stock falls 17% Mar 01
Full year 2023 earnings released: EPS: US$2.96 (vs US$0.066 in FY 2022) Feb 23
Insulet Corporation Provides Unaudited Revenue Guidance for the Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024 Feb 23
Now 20% undervalued Feb 19
Insulet Corporation Announces Board Changes Jan 19
Insulet Corporation to Report Q4, 2023 Results on Feb 22, 2024 Jan 12
Director & Advisor recently sold €2.3m worth of stock Nov 16
Now 21% undervalued after recent price drop Nov 07
Insulet Corporation Provides Revenue Guidance for the Fourth Quarter and Year Ending December 31, 2023 Nov 03
Third quarter 2023 earnings released: EPS: US$0.74 (vs US$0.075 loss in 3Q 2022) Nov 03
Insulet Announces FDA 510(k) Clearance of the Omnipod® 5 App for iPhone Oct 24
New minor risk - Share price stability Oct 14 Insulet Corporation Announces CFO Transition
Insulet Corporation to Report Q3, 2023 Results on Nov 02, 2023 Sep 29
Now 21% undervalued after recent price drop Sep 21
Insulet Announces Full Market Release of Omnipod 5 Automated Insulin Delivery System in Germany Aug 29
Second quarter 2023 earnings released: EPS: US$0.39 (vs US$0.51 loss in 2Q 2022) Aug 09 Insulet Corporation to Report Q2, 2023 Results on Aug 08, 2023 Jul 06
Insulet Corporation Announces Omnipod 5 Automated Insulin Delivery System Is Now Available in the United Kingdom Jun 21
Insider recently bought €933k worth of stock May 26 Bret Christensen, Executive Vice President, Chief Commercial Officer Will Be Leaving Insulet Corporation
First quarter 2023 earnings released: EPS: US$0.34 (vs US$0.40 in 1Q 2022) May 05
Executive VP recently sold €367k worth of stock Apr 08
Full year 2022 earnings released: EPS: US$0.066 (vs US$0.25 in FY 2021) Feb 24
Insulet Corporation (NasdaqGS:PODD) acquired Assets of Automated Glucose Control LLC for $25 million. Feb 15
Insulet Corporation to Report Q4, 2022 Results on Feb 23, 2023 Jan 13
Insulet Corporation Announces Executive Changes Dec 15
Executive VP & Chief Commercial Officer recently sold €854k worth of stock Nov 22
Insulet Corporation Announces Medical Device Correction for the Omnipod 5 Automated Insulin Delivery System Nov 15
Third quarter 2022 earnings released: US$0.075 loss per share (vs US$0.18 profit in 3Q 2021) Nov 05
Insulet Corporation Issued Voluntary Medical Device Correction for Omnipod DASH® Personal Diabetes Manager on October 17, 2022 Nov 05 Insulet Corporation Provides Revenue Guidance for the Quarter Ending December 31, 2022
Insulet Corporation to Report Q3, 2022 Results on Nov 03, 2022 Sep 23
Executive VP & Chief Commercial Officer recently sold €768k worth of stock Aug 27
Insulet Corporation Announces FDA Clearance of Omnipod® 5 for Children Aged Two Years and Older with Type 1 Diabetes Aug 23
Second quarter 2022 earnings released: US$0.51 loss per share (vs US$0.38 loss in 2Q 2021) Aug 05
Insulet Corporation Provides Revenue Guidance for the Quarter Ending September 30, 2022 and Year Ending December 31, 2022 Aug 05
Insulet Corporation Announces Full Market Release of Omnipod 5 Automated Insulin Delivery System Aug 02
Insulet Corporation to Report Q2, 2022 Results on Aug 04, 2022 Jul 01
Executive VP & COO recently sold €1.2m worth of stock Jun 09
Omnipod(R) 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years Jun 04
Dexcom Says Not in Active Merger Talks Jun 02
Dexcom Reportedly in Talks to Acquire Insulet May 24
First quarter 2022 earnings released May 06 Insulet Corporation Provides Revenue Guidance for the Quarter Ending June 30, 2022 and Full Year Ending December 31, 2022
Insulet Presents New Omnipod® 5 System Data for Type 1 and Type 2 Diabetes Apr 28
Insulet Corporation, Annual General Meeting, May 24, 2022 Apr 13
Insulet Corporation to Report Q1, 2022 Results on May 05, 2022 Apr 08
Insulet Corporation Provides Revenue Guidance for the First Quarter Ending March 31, 2022 and Year Ending December 31, 2022 Feb 24
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Insulet Corporation Promotes Inclusivity for People with Diabetes Through Nintendo® Video Game Animal Crossing™: New Horizons Feb 18
Insulet Corporation Announces Board Changes Feb 08
Insulet Corporation Announces FDA Clearance of Its Omnipod 5 Automated Insulin Delivery System, First Tubeless System with Smartphone Control Jan 30
Third quarter 2021 earnings released: EPS US$0.18 (vs US$0.18 in 3Q 2020) Nov 05
Executive VP & Chief Commercial Officer recently sold €750k worth of stock Sep 01
Executive VP & COO recently sold €1.0m worth of stock Aug 20
Insulet Corporation Announces FDA Clearance of Lyumjev® Rapid-Acting Insulin for Use with Omnipod® Products in the United States Aug 17
Insulet Introduces Omnipod DASH System at Australasian Diabetes Congress Aug 12
Second quarter 2021 earnings released: US$0.38 loss per share (vs US$0.22 profit in 2Q 2020) Aug 06
Insulet Corporation Announces Notice of Settlement of Derivative Suit Jul 01
Insulet Corporation’S Omnipod® 5 Automated Insulin Delivery System Pivotal Studies Demonstrate Improved Outcomes Across the Lifespan from Ages 2 to 70 Years Jun 29
Insulet Corporation to Present New Clinical Data for Preschool Children and Adults Using the Omnipod 5 System Jun 25
Executive VP & COO recently sold €409k worth of stock Jun 06
Independent Director recently sold €179k worth of stock May 15
Insulet Corporation Announces Revenue Guidance for the Year Ending December 31, 2021 May 07 Rentabilidad de los accionistas GOV DE Medical Equipment Mercado DE 7D 1.2% 1.8% 2.0% 1Y 49.8% -3.5% 15.2%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: GOV superó a la industria German Medical Equipment, que obtuvo un rendimiento del -3.5% el año pasado.
Rentabilidad vs. Mercado: GOV superó al mercado German, que obtuvo un rendimiento del 15.2% el año pasado.
Volatilidad de los precios Is GOV's price volatile compared to industry and market? GOV volatility GOV Average Weekly Movement 4.6% Medical Equipment Industry Average Movement 6.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.0% 10% least volatile stocks in DE Market 2.4%
Precio estable de las acciones: GOV no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado German.
Volatilidad a lo largo del tiempo: La volatilidad semanal de GOV (5%) se ha mantenido estable durante el año pasado.
Acerca de la empresa Insulet Corporation desarrolla, fabrica y vende sistemas de administración de insulina para diabéticos insulinodependientes. La plataforma Omnipod de la empresa incluye el Sistema Automatizado de Administración de Insulina Omnipod 5 (Omnipod 5), que incluye un algoritmo AID patentado integrado en el Pod que se integra con un monitor continuo de glucosa de terceros para obtener valores de glucosa mediante comunicación inalámbrica bluetooth; Omnipod DASH, que incluye un Pod con bluetooth controlado por un gestor personal de la diabetes similar a un teléfono inteligente con una interfaz de usuario de pantalla táctil en color; y Omnipod GO, un sistema de administración de insulina autónomo y portátil que proporciona una tasa fija de insulina continua de acción rápida durante 72 horas. La empresa vende sus productos principalmente a través de distribuidores independientes y canales de farmacia, así como directamente en Estados Unidos, Canadá, Europa, Oriente Medio, Australia e internacionalmente.
Mostrar más Resumen de fundamentos de Insulet Corporation ¿Cómo se comparan los beneficios e ingresos de Insulet con su capitalización de mercado? Estadísticas fundamentales de GOV Capitalización bursátil €18.91b Beneficios(TTM ) €405.12m Ingresos (TTM ) €1.91b
46.7x Ratio precio-beneficio (PE)
9.9x Ratio precio-ventas (PS) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de GOV Ingresos US$1.98b Coste de los ingresos US$595.20m Beneficio bruto US$1.39b Otros gastos US$967.80m Beneficios US$420.90m
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
Feb 20, 2025
Beneficios por acción (BPA) 6.00 Margen bruto 70.00% Margen de beneficio neto 21.22% Ratio deuda/patrimonio 123.4%
¿Cómo se ha desempeñado GOV a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2025/01/31 13:28 Precio de las acciones al final del día 2025/01/30 00:00 Beneficios 2024/09/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Insulet Corporation está cubierta por 58 analistas. 22 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Anand Vankawala Avondale Partners Jeffrey Johnson Baird null null Baird
Mostrar 55 más analistas 
